



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Stephen James et al. Art Unit : 1614  
Serial No. : 10/615,252 Examiner :  
Filed : July 8, 2003  
Title : METHODS FOR IDENTIFICATION OF COMPOUNDS MODULATING  
INSULIN RESISTANCE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the attached form PTO-1449. A copy of a communication from a foreign patent office in a counterpart application is also enclosed. The communication is dated June 25, 2003.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 13425-137001.

Respectfully submitted,

Date: October 21, 2003

Jack Brennan  
Jack Brennan  
Reg. No. 47,443

Fish & Richardson P.C.  
45 Rockefeller Plaza, Suite 2800  
New York, New York 10111  
Telephone: (212) 765-5070  
Facsimile: (212) 258-2291

30165526.doc

## CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/22/03


Date of Deposit

Gina Maldonado

Signature

GINA MALDONADO

Typed or Printed Name of Person Signing Certificate



Substitute Form PTO-1449

(Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAttorney's Docket No.  
13425-137001Application No.  
10/615,252Information Disclosure Statement  
by Applicant

(Use several sheets if necessary)

Applicant  
Stephen James et al.Filing Date  
July 8, 2003Group Art Unit  
1614

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	6,020,374	02/01/2000	Geier et al.			
	AB	6,110,970	08/29/2000	Nudelman et al.			

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AC	1 010 433	06/21/2000	EP				
	AD	1 170 008	01/09/2002	EP				
	AE	2 309 696	08/06/1997	GB				
	AF	11-302173	11/02/1999	JP				
	AG	2001-348340	12/18/2001	JP				
	AH	WO 98/21592	05/22/1998	WIPO				
	AI	WO 98/32017	07/23/1998	WIPO				
	AJ	WO 99/11659	03/11/1999	WIPO				
	AK	WO 00/08048	02/17/2000	WIPO				
	AL	WO 00/21979	04/20/2000	WIPO				
	AM	WO 00/52033	09/08/2000	WIPO				
	AN	WO 01/38322	05/31/2001	WIPO				
	AO	WO 01/70675	09/27/2001	WIPO				
	AP	WO 02/06307	01/24/2002	WIPO				
	AQ	WO 02/08273	01/31/2002	WIPO				

## Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AR	Araki et al., "Alternative Pathway of Insulin Signalling in Mice with Targeted Disruption of the IRS-1 Gene" <i>Nature</i> 372: 186-190 (1994)
	AS	Cheung et al., "Signaling to Chromatin Through Histone Modifications" <i>Cell</i> 103: 263-271 (2000)
	AT	Cross et al., "Insulin Activates Protein Kinase B, Inhibits Glycogen Synthase Kinase-3 and Activates Glycogen Synthase by Rapamycin-Insensitive Pathways in Skeletal Muscle and Adipose Tissue" <i>FEBS Lett</i> 406: 211-215 (1997)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-137001	Application No. 10/615,252
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Stephen James et al.	
		Filing Date July 8, 2003	Group Art Unit 1614

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AU	Elchebly et al., "Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the Protein Tyrosine Phosphatase-1B Gene" <i>Science</i> 283: 1544-1548 (1999)
	AV	Ewart-Toland et al. "Effect of the Genetic Background on the Reproduction of Leptin-Deficient Obese Mice" <i>Endocrinology</i> 140: 732-738 (1999)
	AW	Fantin et al., "Mice Lacking Insulin Receptor Substrate 4-Exhibit Mild Defects in Growth, Reproduction, and Glucose Homeostasis" <i>Am J Physiol Endocrinol Metab</i> 278: E127-133 (2000)
	AX	Gray et al., "The Human Histone Deacetylase Family" <i>Exp Cell Res</i> 262: 75-83 (2001)
	AY	Johnstone, "Histone Deacetylase Inhibitors: Novel Drugs for the Treatment of Cancer" <i>Nature Reviews</i> 1: 287-299 (2002)
	AZ	Kelly et al., "Suberoylamilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity" <i>Proc. Amer. Soc. Clin. Oncol.</i> 20: 87a (2001)
	AAA	Knoepfler et al., "Sin Meets NuRD and Other Tails of Repression" <i>Cell</i> 99: 447-450 (1999)
	ABB	Liu et al., "Insulin Receptor Substrate 3 is not Essential for Growth or Glucose Homeostasis" <i>J. Biol. Chem.</i> 274: 1)8093-18099 (1999)
	ACC	Luna et al. "Oral Agents in the Management of Type 2 Diabetes Mellitus", <i>American Family Physician</i> 63(9):1747-1756
	ADD	Marks et al., "Histone Deacetylase Inhibitors as New Cancer Drugs" <i>Current Opinion in Oncology</i> 13: 477-483 (2001)
	AEE	Ng et al., "Histone Deacetylases: Silencers for Hire" <i>Trends Biochem Sci</i> 25: 121-126 (2000)
	AFF	Patti et al., "Activation of the Hexosamine Pathway by Glucosamine... Muscle" <i>Diabetes</i> 48:1562
	AGG	Qiao et al., "Identification of enhanced Serine Kinase Activity in Insulin Resistance" <i>J. Biol. Chem.</i> 274: 10625-10632 (1999).
	AHH	Roth et al., "Histone Acetyltransferases" <i>Annu. Rev. Biochem.</i> 70: 81-120 (2001)
	AII	Shepherd et al., "Phosphoinositide 3-Kinase: The Key Switch Mechanism in Insulin Signalling" <i>Biochem J.</i> 333: 471-490 (1998)
	AJJ	Strahl et al., "The Language of Covalent Histone Modifications" <i>Nature</i> 403: 41-45 (2000)
	AKK	Sun et al., "Structure of the Insulin Receptor Substrate IRS-1 Defines a Unique Signal Transduction Protein" <i>Nature</i> 352: 73-77 (1991)
	ALL	Tamemoto et al., "Insulin Resistance and Growth Retardation in Mice Lacking Insulin Receptor Substrate-1" <i>Nature</i> 372: 182-186 (1994)
	AMM	Tu et al., "Src Homology 3 Domain-Dependent Interaction of Nck-2 with Insulin Receptor Substrate-1" <i>Biochem J.</i> 354: 315-322 (2001)
	ANN	Vigushin et al., "Histone Deacetylase Inhibitors in Cancer Treatment" <i>Anticancer Drugs</i> 13: 1-13 (2002)
	AOO	White et al., "Insulin Rapidly Stimulates Tyrosine Phosphorylation of a Mr-185,000 Protein in Intact Cells" <i>Nature</i> 318: 183-186 (1998)
	APP	White et al., "The IRS-Signalling System: A Network of Docking Proteins that Mediate Insulin Action" <i>Mol Cell Biochem.</i> 182: 3-11 (1998)
	AQQ	Withers et al., "Disruption of IRS-2 Causes Type 2 Diabetes in Mice" <i>Nature</i> 391: 900-904 (1998)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-137001	Application No. 10/615,252
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Stephen James et al.		
		Filing Date July 8, 2003	Group Art Unit 1614	

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	ARR	Wolffe et al., "Review: Chromatin Structured Features and Targets that Regulate Transcription" <i>J. Struct. Biol.</i> 129: 102-122 (2000)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	